The Global Health Body Issues Alert Over Severe Lack of Weight-Loss Jabs

Under a tenth of people that would benefit from weight-loss injections such as Wegovy have access to them, warns the WHO as it releases its inaugural advice on the medications.

Given in excess of 1,000,000,000 individuals worldwide currently obese, it is urging increased and just availability to these injectable treatments.

Per projections, in excess of 2,000,000,000 could be obese by 2030 unless action is taken.

"Our new guidance recognises that excess weight is a long-term condition that can be managed with thorough and ongoing care," said WHO director-general Tedros Adhanom Ghebreyesus.

Significant expense, limited production capacity, and logistical bottlenecks are major hurdles to universal availability to the treatments that can help people shift substantial weight, explains the agency.

Skinny Jab Scarcity

Despite the current most favorable scenario, the manufacturing of these medications would only suffice for about 100 million people – less than 10% of those who need them, per the WHO.

The guideline urges governments and firms to increase availability, by strategies such as licensing agreements.

The intellectual property rights on semaglutide – the primary ingredient of the drug Wegovy – is due to expire in a number of countries in 2026.

How Weight-Loss Injections Operate

These medications mimick a body's own hormone to slow digestion, curb appetite and enhance satiety so individuals eat less.

Individuals typically begin shedding pounds after several weeks of starting on the weekly injections.

Evidence points to users may regain a significant portion after a year of discontinuing the treatment, when their normal food cravings come back.

To be overweight or obese raises your risk for contracting health problems, including type 2 diabetes, heart disease, brain attack, and specific malignancies.

Excess weight impacts people in all nations and was linked to 3.7 million deaths worldwide in 2024, as per the WHO.